Vizsgálati helyszín
Richmond Behavioral Associates
Staten Island, New York 10314, Egyesült ÁllamokMég nincs intézményhez kötve
- 17futó vizsgálat
- 17lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 35 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis21 vizsgálat
- 2. fázis11 vizsgálat
- Állapot
- Lezárult13 vizsgálat
- Fut, nem toboroz10 vizsgálat
- Toboroz6 vizsgálat
- Leállították3 vizsgálat
- Még nem toboroz1 vizsgálat
- Felfüggesztve1 vizsgálat
- Visszavonták1 vizsgálat
- Fő szponzor
- Bristol-Myers Squibb4 vizsgálat
- Eli Lilly and Company3 vizsgálat
- Xenon Pharmaceuticals Inc.3 vizsgálat
- Cassava Sciences, Inc.2 vizsgálat
- Intra-Cellular Therapies, Inc.2 vizsgálat
- és még 17
Futó vizsgálatok
Még nem toboroz
A Study of Brenipatide in Participants With Major Depressive Disorder
NCT07928245· 2. fázis· Eli Lilly and Company· Forrás
Contact: Adam Smith (principal investigator)
Toboroz
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Romana Kulikova, Site 0032
Fut, nem toboroz
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07172516· 3. fázis· Xenon Pharmaceuticals Inc.· Forrás
Toboroz
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Peter Weiden, Site 0033
Toboroz
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Romana Kulikova, Site 2619
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
NCT06951698· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Peter Weiden, Site 0030
Fut, nem toboroz
An Open-Label Study of Azetukalner in Major Depressive Disorder
NCT06922110· 3. fázis· Xenon Pharmaceuticals Inc.· Forrás
Fut, nem toboroz
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT06709014· 3. fázis· Annovis Bio Inc.· Forrás
Fut, nem toboroz
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379· 3. fázis· Xenon Pharmaceuticals Inc.· Forrás
Toboroz
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
NCT06706674· 3. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCT06229210· 3. fázis· Intra-Cellular Therapies, Inc.· Forrás
Fut, nem toboroz
ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
NCT05889273· 2. fázis· MapLight Therapeutics· Forrás
Fut, nem toboroz
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
NCT05711940· 3. fázis· COMPASS Pathways· Forrás
Fut, nem toboroz
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
ERG Components in Schizophrenia and Bipolar Disorder Type I
NCT03788811· diaMentis Inc.· Forrás
Fut, nem toboroz
An Open Label Study of CM-AT for the Treatment of Children With Autism
NCT02649959· 3. fázis· Curemark· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
NCT07046494· 2. fázis· Rapport Therapeutics Inc.· Forrás
Lezárult
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
NCT06836063· 2. fázis· Suven Life Sciences Limited· Forrás
Lezárult
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122· Boehringer Ingelheim· Forrás
Lezárult
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
NCT06179108· 2. fázis· LB Pharmaceuticals Inc.· Forrás
Leállították
Open-label Extension for Phase 3 Clinical Trials of Simufilam
NCT05575076· 3. fázis· Cassava Sciences, Inc.· Forrás
Lezárult
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05081245· 2. fázis· MapLight Therapeutics· Forrás
Lezárult
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
NCT05536414· 2. fázis· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás
Lezárult
A Study of Seltorexant in Participants With Probable Alzheimer's Disease
NCT05307692· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
NCT05122650· 2. fázis· Jazz Pharmaceuticals· Forrás
Leállították
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
NCT05026177· 3. fázis· Cassava Sciences, Inc.· Forrás
Lezárult
Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder
NCT04745026· 2. fázis· Jazz Pharmaceuticals· Forrás
Lezárult
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
NCT04770220· 3. fázis· Alzheon Inc.· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
NCT04801420· 2. fázis· Pfizer· Forrás
Toboroz
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
NCT03887715· LivaNova· Forrás
Contact: Laura Yates, BSN
Leállították
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132· 3. fázis· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás
Hibát jelzek